Eytan Ruppin, MD, PhD

Eytan is Chief of the Cancer Data Science Lab at the NCI.  Prior to that, he was Director of the University of Maryland’s Center for Bioinformatics and Computational Biology, where he also served as a professor of computer science.

Eytan has co-founded a number of precision medicine and cancer drug discovery startups, including Metabomed, Medaware, and Pangea Biomed.  He is a member of the editorial boards of EMBO Reports and Molecular Systems Biology, and a fellow of the International Society for Computational Biology.  His recent research focuses on developing new computational approaches for synthetic lethal and transcriptomics-based precision oncology and immunotherapy.

Eytan received his MD and PhD in computer science from Tel Aviv University, where he also served as a professor of computer science and medicine. He divested of his shares in Pangea when he joined the NCI.